247 results about "Isolated cell" patented technology

Methods for generating human vascular leptomeningeal cells (VLMCs) from human oligodendrocyte progenitor cells (OPCs) are provided using chemically-defined culture media that allow for generation of differentiated cells in a 34-day culture protocol. Methods of generating human VLMCs from human pluripotent stem cells using chemically-defined culture media in a 40 day culture protocol are also provided. Culture media, isolated cell populations, and kits are also provided.

An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is described. Methods of generating same and using same are also described.

The invention relates to the technical field of biopharmaceutical equipment, in particular to a sterile culture method and a sterile culture system. The sterile culture system comprises a cell preparation device, an incubator and a cell culture device, the cell preparation device comprises a preparation chamber, and a first sealing valve is arranged on the side wall of the preparation chamber; the incubator is provided with a culture chamber, a second sealing valve is arranged on the side wall of the culture chamber, and the second sealing valve is used for being matched with the first sealing valve, so that the incubator and the cell preparation device are in sealed butt joint or sealed separation; the cell culture device is used for accommodating the culture box, supplying power and gas to the culture box and controlling the cell growth environment in the culture box. As the cells always grow in the sterile environment, the pollution risk is low, frequent sterilization is not needed, the normal growth of the cells is prevented from being influenced by frequent sterilization, the culture time is saved, and the cell preparation and culture efficiency is high.

The invention provides a multi-channel viscoelastic micro-fluidic chip, a manufacturing method and a method for separating MCF-7 cells. The multi-channel viscoelastic micro-fluidic chip comprises a first multi-stage shunting module, a pipette, a second multi-stage shunting module, a single-stage viscoelastic micro-fluidic sub-module and a third multi-stage shunting module, the first multi-stage shunting module is connected with one inlet of the single-stage viscoelastic micro-fluidic sub-module through a pipette; the second multi-stage shunting module is connected with the other inlet of the single-stage viscoelastic micro-fluidic sub-module; and the outlet of the single-stage viscoelastic micro-fluidic sub-module is connected with the third multi-stage shunting module. According to the method, the PEO solution is used as sheath fluid, and the action of elastic force is introduced to cells, so that CTC can be directly separated from undiluted human blood in an ultrahigh-flux manner, and the limitation that erythrocytes need to be split and a blood sample needs to be diluted by dozens of times before cell separation in traditional inertial microfluidics is broken through; and the complexity of operation and the risk of sample pollution are reduced.

Fusion polypeptides are provided and comprise at least two ligand binding domains and a fragment crystallizable (Fc) region of immunoglobulin G (IgG). The ligand binding domains include an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-25 and / or one of the at least two ligand binding domains binds modulates B cell activity while the other modulates T cell activity. Isolated nucleic acids, vectors, and isolated cells encoding or including the fusion peptides are further provided. Pharmaceutical compositions include the fusion peptides and a pharmaceutically-acceptable vehicle, carrier, or excipient. Methods of treating Sjögren's Syndrome and / or Systemic Lupus Erythematosus are also provided and comprise administering to a subject in need thereof the fusion polypeptide including the two ligand binding domains and the Fc region of IgG.

The disclosure relates to method and kits for highly specific detection and quantification of extracellular vesicles (EVs) by targeting at least two EV surface markers using binding reagents. The binding reagents contain hybridisation sequences and primer binding regions, the hybridisation sequences are ligated and amplified using primers. The disclosure further relates to methods and kits for isolating EVs using capture entities, splint entities and staple entities wherein the capture entity comprises a labile linkage.

The invention relates to the field of medical image processing, and particularly discloses a TLS structure sketching system and method based on artificial intelligence, and the method comprises the steps: S1, image preprocessing: carrying out the standardization processing of an input HE staining section image, firstly separating cell nucleus and cytoplasm staining components through a color deconvolution algorithm, and highlighting the nucleoplasm contrast of lymphocytes; then strengthening the cell contour boundary by adopting an edge detection algorithm, and connecting the fracture edge through morphological operation to form a continuous and clear cell boundary mask; s2, morphological feature extraction: performing single cell segmentation based on the preprocessed image, and extracting geometric features and texture features of each cell; through machine learning model training, distinguishing lymphocytes and non-lymphocytes according to the characteristics, and generating a lymphocyte distribution probability graph; and S3, preliminarily identifying the aggregated area. By adopting the technical scheme of the invention, the TLSs differentiation stage can be identified, and the identification accuracy can be improved by combining morphological characteristics and spatial distribution characteristics.

Provided is a method and apparatus for cell staining without cell loss, and more particularly, to a method and apparatus for cell staining without cell loss during treatment of a staining reagent or washing reagent by immobilizing cells to be analyzed in a phase change material before staining. A method for cell staining without cell loss may effectively prevent cell loss during staining and analysis of rare cells that are becoming important in clinical diagnosis, and thus may facilitate observation, analysis and diagnosis thereby even with a trace amount of sample. In addition, as the method for cell staining without cell loss allows immobilization of cells, it makes discrimination and isolation of single cells easy, and may be effectively used in analysis of the isolated cells.

The present invention relates to a method for producing a skin tissue model, comprising: (a) isolating and culturing fibroblasts and keratinocytes from skin tissue; (b) preparing a bioink composition for a dermal layer and a bioink composition for an epidermal layer, the bioink composition containing the isolated cells; and (c) producing a skin tissue model using the bioink composition for a dermal layer and the bioink composition for an epidermal layer.

Methods for generating mature somatostatin+ interneurons from human forebrain neural progenitor cells are provided using chemically-defined culture media in a two-stage culture protocol. The mature somatostatin+ interneurons are generated from medial ganglionic eminence neural progenitor cells (MGE-NPCs), which themselves are differentiated from pluripotent stem cells. Culture media, isolated cell populations and kits are also provided.

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.

To provide: a cell culture vessel that can achieve both detachability and proliferation ability, that is, can facilitate cell detachment without reducing the proliferation ability of cells; and a cell detachment method using the cell culture vessel, provided is a cell detachment method of detaching, through use of a culture vessel having a periodic recess / protrusion pattern on a culture surface, comprising a detachment step of: causing a vibrating unit in which, when an observation image of a cross section perpendicular to the culture surface is obtained, a length Lcp of a contour of the cell on the culture surface side in a measurement region of the observation image and a length Lf of the measurement region in a direction parallel to the culture surface satisfy Lcp>Lf; and transmitting the ultrasonic vibration to the cell, to thereby detach the cell from the culture surface.

The invention relates to the technical field of biology, and discloses a construction method of a gastric cancer organoid culture system, which comprises the following steps: preparation of a conditioned medium: culturing L-WRN cells and collecting the conditioned medium; preparing a gastric cancer organoid culture medium, and mixing the conditioned culture medium, the basic culture medium, a plurality of growth factors and additives; and extraction and culture of organoid: separating cells from gastric cancer tissues, mixing the cells with matrigel, and culturing by using the prepared culture medium. According to the method, the repeatability and the stability of the organoid model are improved, the response consistency of the organoid in drug screening is improved, and the reliability of the model in disease mechanism research and personalized medical application is guaranteed.

A method of generating cells of the T cell lineage is provided that involves culturing a sample comprising stem cells or progenitor cells with an engineered Notch ligand conjugated to a suspension support and isolating cells of the T cell lineage. In one embodiment, the cells of the T-cell lineage are progenitor T cells or mature T cells. Compositions, kits and uses thereof are also provided.

To provide an isolated cell capable of regulating cough.SOLUTION: The problem is solved by an isolated laryngeal PCC expressing Calhm3 protein.SELECTED DRAWING: None

The present application relates to (i) a variant adeno-associated virus (AAV) capsid polypeptide comprising a peptide insertion in the variable region IV or in the variable region VIII relative to a wild-type AAV capsid polypeptide, wherein the peptide insertion comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1-29 or an amino acid sequence having at least 70% sequence identity thereto, (ii) an isolated nucleic acid encoding the aforementioned variant polypeptide, (iii) a recombinant polynucleotide comprising the aforementioned nucleic acid, and (iv) an isolated cell comprising the aforementioned polypeptide, nucleic acid or recombinant polynucleotide. The present application further relates to (v) an adeno-associated virus (AAV) vector comprising the aforementioned variant polypeptide, (vi) a pharmaceutical composition comprising the aforementioned AAV vector as well as (vii) the use of the aforementioned vector or pharmaceutical composition in preventing or treating an ocular disease. Finally, the present application relates to (viii) a method of delivering a heterologous nucleic acid to a retinal cell and (ix) a method of delivering a heterologous nucleic acid to the eye of a subject.

An apparatus and method for T-cell separation, activation, transduction and expansion. Three-dimensional (3D) bioreactors may be employed that include antibody coatings. Such 3D bioreactors can be employed for T-cell separation from peripheral blood mononuclear cells including attachment of T-cells to the 3D bioreactor surface for activation and transduction by lentivirus vectors to produce CAR T-cells. The CAR T-cells can then be expanded in a separate downstream bioreactor therein providing a scalable automated system.

The invention relates to the technical field of biocompatible compositions, in particular injectable biocompatible compositions. In particular, the invention relates to a particular biocompatible composition comprising a solution and heterogeneous cellular elements suspended in said solution, which elements are selected from isolated cells, cellular microtissues, cell clusters and mixtures thereof, at least two of said cellular elements having a different density and / or size and / or number of cells.

The invention relates to the fields of molecular biology and virology, and provides a method for preparing a specific MHC haplotype-derived cell-binding virus. The method comprises the following steps: firstly, obtaining chick embryos of different haplotypes, separating CEF cells, transiently expressing exogenous fluorescent protein through electrotransfection, then carrying out virus inoculation, carrying out flow sorting to obtain a fluorescent positive cell population carrying MDV, and carrying out quantitative analysis on the cell population to obtain the specific MHC haplotype chicken Marek's Disease Virus (MDV), thereby obtaining the specific MHC haplotype chicken Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus. And carrying out in-vitro propagation to obtain the purified MDV with a specific haplotype source. The purified virus can provide a test material for related research of haplotype on virus infection, and can be widely applied to in-vitro purification of different cell binding viruses and related research of specific MHC molecule presenting virus peptides. The method disclosed by the invention is beneficial to carrying out related research aiming at the host immune response of the virus and analyzing the hereditary basis of haplotype to MDV differential resistance, and is expected to be applied to preparation of vaccine virus.

To provide a cell including a cell expressing CD24, and related method of use and creation thereof.SOLUTION: Provided is an isolated cell including modification for increasing reduced expression of MHC class I and / or MHC class II human leukocyte antigens and expression of CD24 in a cell. In some embodiments, the cell includes reduced expression of MHC class I and MHC class II human leukocyte antigens.SELECTED DRAWING: None

The disclosure relates to a truncated recombinant L1 protein of Human papillomavirus (HPV), a recombinant polynucleotide encoding the protein, a recombinant vector comprising the polynucleotide, an isolated cell comprising the recombinant vector, a composition comprising the protein, and a method for producing the protein. The disclosure also relates to an HPV virus-like particle (VLP) comprising the protein, an immunogenic composition comprising the protein or the VLP, and a method for inducing an immune response to HPV in an individual.

The present disclosure provides, among other things, a method of isolating and expanding gamma delta (γδ) T cells, wherein the method comprises: (a) isolating non-hematopoeitic tissue by biopsy or explant, and (b) culturing the isolated non-hematopoeitic tissue in the absence of a three-dimensional scaffold or grid, thereby expanding and isolating gamma delta (γδ) T cells.

A heterogeneous population of cells are separated and collected according to a method. The heterogeneous population of cells in a paramagnetic medium are placed in a fluidic channel in which the fluidic channel comprises two or more outlets. The heterogeneous population of cells in the fluidic channel are separated based on differences in magnetic susceptibility and density of the heterogeneous population of cells. Fluid comprising the separated cells is withdrawn from the two or more outlets using variable flow rates by fluidic pumps at respective ones of the two or more outlets simultaneously to fractionalize the fluid comprising the separated cells across the two or more outlets by manipulation of the variable flow rates relative to one another.

Plant cell fate and development is altered by treating cells with cellular reprogramming factors. Embryogenesis inducing embryogenesis factor genes and / or morphogenic developmental genes are used as cellular reprogramming factors, specifically comprising polypeptides or polynucleotides encoding gene products for generating doubled haploids or haploid plants from gametes. Maize microspores treated by contacting the isolated cells with an exogenous purified, recombinant embryogenesis inducing embryogenesis factor gene products and / or morphogenic developmental gene polypeptide results in embryogenesis. The gametes of a maize plant develop into embryoids when transformed with a genetic construct including regulatory elements and structural genes capable of acting in a cascading fashion to alter cellular fate of plant cells. Embryogenesis factor proteins and / or developmental morphogenic proteins expressed from a genetic construct are used for ex situ treatment methods and for in planta cellular reprogramming.

A method for generating human midbrain immature neurons and mature dopaminergic neurons from neural progenitor cells is provided. The immature and mature midbrain neurons are obtained from neural progenitor cells such as committed midbrain neural stem cells (NSCs) and midbrain neural progenitor cells (midbrain NPCs), which are themselves generated from human pluripotent stem cells. The method for generating midbrain immature neurons and mature neurons uses a chemically defined medium that enables the generation of mature dopaminergic neurons in just 23 days. Media, isolated cell populations, and kits are also provided.

The invention relates to a microfluidic device. Said device has at least one magnetic marker, which is designed to bind to surface proteins of cells (30, 31), at least one mixing region, which is designed to bring the at least one magnetic marker into contact with the cells (30, 31), and at least one separating region (14), into which the cells (30, 31) can be introduced and which has at least one magnet (15), preferably on an upper side (16). A method for separating cells by means of the microfluidic device comprises bringing cells (30, 31) into contact with at least one magnetic marker in the mixing region, sedimenting the cells (30, 31) in the separating region (14), applying a magnetic field in the separating region (14), and discharging cells (31) marked with the marker from the separating region by means of a fluid flow (61).

Provided in the present application is a radiative cooling film, comprising a base film layer, wherein the base film layer comprises a resin matrix, and a plurality of isolated cells, a plurality of separate first particles and a plurality of cell-enveloped second particles, which are all dispersed in the resin matrix. In the radiative cooling film using the technical solution of the present application, air in the cells in the base film layer is a substance with a low refractive index, the first particles and the second particles are each a substance with a high refractive index, and there are differences between the refractive index of the air in the cells and the refractive indices of the first particles and the second particles, thereby improving the reflectivity of the base film layer; by controlling the differences between the refractive index of the air in the cells and the refractive indices of the first particles and the second particles, high reflectivity is achieved; moreover, since the radiative cooling film of the present application does not contain a metal coating, signal shielding can be avoided, which is beneficial to the wide application of the radiative cooling film.

The invention provides methods of isolating CD 127lo / − immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.

Described are methods and systems for enhanced dissociation of cells from a solid biological tissue sample. In some embodiments, a self-contained cartridge apparatus includes a first chamber for receiving the tissue sample, enables ultrasonic energy from a transducer assembly of a processing unit to dissociate cells from the sample in the first chamber, and collect viable cells of interest from an aqueous suspension in a second chamber fluidly connected to the first chamber via a channel. In some embodiments, to enhance dissociation of viable cells, a filter device includes a tubular body configured to be telescopically inserted into a container containing the tissue sample in an aqueous fluid. The filter device also includes a cell-filter mesh that covers a bottom opening of the tubular body and that is configured to compress the tissue sample to expel cells from the sample when the filter device is fully inserted into the container.

The present application provides methods for generating human midbrain immature neurons and mature dopaminergic neurons from neural progenitor cells. In some embodiments, immature and mature midbrain neurons are obtained from neural progenitor cells, such as targeted midbrain neural stem cells (NSCs) and midbrain neural progenitor cells (midbrain NPCs), while they themselves are generated from human pluripotent stem cells. Methods for generating immature and mature neurons of the midbrain use a chemically defined medium that allows for the generation of mature dopaminergic neurons within a short of 23 days. Media, isolated cell populations, and kits are also provided.